United Airlines Reports Mixed Financial Results
The stock of United Airlines (UAL) is down 3% after the carrier reported mixed financial results for this year’s second quarter and offered new forward guidance.The Chicago-based airline reported earnings per share (EPS) of $3.87 U.S., which was ahead of the $3.81 U.S. expected among analysts. However, revenue of $15.24 billion U.S. came in below Wall Street forecasts of $15.35 billion U.S. Sales were up only 1.7% from a year earlier.Despite the mixed print, United Airlines’ management team issued new guidance for this year, saying that travel demand is picking up after a difficult start to 2025. The carrier now expects earnings of $9 U.S. to $11 U.S. per share. The midpoint of that guidance matches the $10 U.S. a share that analysts had expected.For the current third quarter, United Airlines expects earnings of $2.25 U.S. to $2.75 U.S. a share, which is also within analysts’ expectations. Travel demand, particularly on domestic U.S. flights, has proven to be weaker than airline executives had expected at the start 2025, sending airfares lower as a result. United Airlines said that operational constraints at Newark International Airport, a major hub for the company, hurt its second-quarter pretax margin by 1.2 percentage points.The Federal Aviation Administration (FAA) cut flights at Newark in May of this year because of air traffic control staffing shortages and some technical issues. Prior to today (July 17), UAL stock was down 7% this year and trading at $88.47 U.S. per share.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


